Início › Câncer de Pulmão de Não Pequenas Células › Louisiana
Ensaios clínicos de Câncer de Pulmão de Não Pequenas Células em Louisiana
25 estudos para Câncer de Pulmão de Não Pequenas Células estão buscando participantes em locais em Louisiana.
Cidades em Louisiana
Texto oficial do estudo (Inglês)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Christus Saint Frances Cabrini Hospital, Alexandria
- LSU Health Baton Rouge-North Clinic, Baton Rouge
- Our Lady of the Lake Physician Group, Baton Rouge
- e mais 11
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 5 de out. de 2026 · NCT04267848Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- Pontchartrain Cancer Center - Covington Office, Covington
- Pontchartrain Cancer Center - Hammond Office, Hammond
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06472245Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- University Medical Center New Orleans, New Orleans
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06498635A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Mary Bird Perkins Cancer Center, Baton Rouge
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT07144280A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- LSU Health Baton Rouge North Clinic ( Site 4003), Baton Rouge
- Our Lady of the Lake Physician Group-Medical Oncology ( Site 0080), Baton Rouge
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06312137Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Pontchartrain Cancer Center, Covington
- Pontchartrain Cancer Center, Hammond
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07222566Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Mary Bird Perkins Cancer Center, Baton Rouge
- Ochsner Health Ochsner Cancer Center - Baton Rouge, Baton Rouge
- Ochsner Clinic Foundation, New Orleans
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT06890598Pan-tumor MRD Study
- Pontchartrain Cancer Center, Covington
- Christus Health Highlands, Shreveport
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT06605404A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Louisiana State University Health Sciences Shreveport, Shreveport
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06875310Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
- Our Lady of the Lake Physician's Group, Baton Rouge
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 21 de set. de 2026 · NCT06745882A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- Mary Bird Perkins Cancer Center, Baton Rouge
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 21 de set. de 2026 · NCT07629960A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Baton Rouge
- Research Site, Shreveport
- Research Site, Shreveport
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 18 de set. de 2026 · NCT06692738Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Clinical Study Site, Covington
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 18 de set. de 2026 · NCT06767514Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Local Institution - 007-994-A, Covington
- Pontchartrain Cancer Center - Covington Office, Covington
RecrutandoFase 2/3
Idades 18 e acima · Todos os sexos · Atualizado em 16 de set. de 2026 · NCT04613596ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Tulane Cancer Center, New Orleans
- Christus Highland/ Boniol, Shreveport
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT05059444A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Mary Bird Perkins Cancer Center, Baton Rouge
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT06119581A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
- LSU Health Sciences Center School of Medicine, New Orleans
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 4 de set. de 2026 · NCT07361562A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Local Institution - 2116, New Orleans
RecrutandoFase 1/2
Idades 12 e acima · Todos os sexos · Atualizado em 27 de mai. de 2026 · NCT03093116Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
- Tulane Cancer Center, New Orleans
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 19 de mai. de 2026 · NCT07154706A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
- Ochsner Health, Jefferson
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 18 de mai. de 2026 · NCT07094204Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Mary Bird Perkins Cancer Center, Baton Rouge
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 15 de mai. de 2026 · NCT05379985Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Ochsner LSU Health Monroe Medical Center, Monroe
- LSU Health Sciences Center at Shreveport, Shreveport
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 17 de mar. de 2026 · NCT06418204SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, New Orleans
RecrutandoEstudo observacional
Todas as idades · Todos os sexos · Atualizado em 28 de out. de 2025 · NCT03452774A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
- Ochsner/MD Anderson Cancer Center, New Orleans
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 24 de out. de 2025 · NCT06228326Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients
- Our Lady of the Lake Regional Medical Center, Baton Rouge
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 18 a 100 · Mulheres · Atualizado em 20 de mar. de 2025 · NCT06659458Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.